| scholarly article | Q13442814 |
| review article | Q7318358 |
| P2093 | author name string | Matsui T | |
| del Monte F | |||
| Hajjar RJ | |||
| Rosenzweig A | |||
| P433 | issue | 6 | |
| P921 | main subject | heart failure | Q181754 |
| gene therapy | Q213901 | ||
| P304 | page(s) | 616-621 | |
| P577 | publication date | 2000-03-01 | |
| P1433 | published in | Circulation Research | Q2599020 |
| P1476 | title | Prospects for gene therapy for heart failure | |
| P478 | volume | 86 |
| Q40655750 | 'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. |
| Q73980929 | A novel procedure for daily measurements of hemodynamical, hematological, and biochemical parameters in conscious unrestrained rats |
| Q37682472 | Abrogation of ventricular arrhythmias in a model of ischemia and reperfusion by targeting myocardial calcium cycling |
| Q44360973 | Adeno-associated virus mediated gene delivery into coronary microvessels of chronically instrumented dogs |
| Q37766138 | Advances in gene-based therapy for heart failure |
| Q37568760 | Antiplatelet therapy attenuates subcellular remodelling in congestive heart failure |
| Q42198000 | CRNK gene transfer improves function and reverses the myosin heavy chain isoenzyme switch during post-myocardial infarction left ventricular remodeling |
| Q21284968 | Cardiomyopathy classification: ongoing debate in the genomics era |
| Q34191737 | Catheter-based antegrade intracoronary viral gene delivery with coronary venous blockade |
| Q35576409 | Clinical gene therapy for nonmalignant disease |
| Q34321370 | Comparative analysis of parvalbumin and SERCA2a cardiac myocyte gene transfer in a large animal model of diastolic dysfunction |
| Q47578575 | Coxsackie‐and‐adenovirus receptor mRNA expression in human heart failure |
| Q36931967 | Current strategies for myocardial gene delivery |
| Q28396645 | Cytoprotection by the modulation of mitochondrial electron transport chain: the emerging role of mitochondrial STAT3 |
| Q80611710 | Detection of TUNEL-positive cardiomyocytes and c-kit-positive progenitor cells in children with congenital heart disease |
| Q24798846 | Down-regulation of the M6P/IGF-II receptor increases cell proliferation and reduces apoptosis in neonatal rat cardiac myocytes |
| Q39737461 | Dual gene therapy with SERCA1 and Kir2.1 abbreviates excitation without suppressing contractility |
| Q24551736 | Ectopic expression of KCNE3 accelerates cardiac repolarization and abbreviates the QT interval |
| Q37122811 | Experimental molecular and stem cell therapies in cardiac electrophysiology |
| Q35724702 | Feasibility of xeno-transplantation |
| Q36596746 | From gene therapy and stem cells to clinical electrophysiology |
| Q45861410 | Gene Therapy in Heart Failure |
| Q26863362 | Gene delivery technologies for cardiac applications |
| Q64379051 | Gene delivery to cardiac muscle |
| Q35218715 | Gene interventions in the beta-adrenergic system for treating heart failure |
| Q35164797 | Gene therapy for cardiovascular angiogenesis |
| Q34497315 | Gene therapy for cardiovascular disorders: is there a future? |
| Q36786243 | Gene therapy in the treatment of heart failure |
| Q35623922 | Gene therapy progress and prospects: noninvasive imaging of gene therapy in living subjects |
| Q35724614 | Gene transfer in cardiac myocytes. |
| Q45865529 | Heart failure: a silver bullet to treat heart failure |
| Q40231910 | Hope for heart failure |
| Q28354203 | Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure |
| Q45886178 | Intramyocardial injection of SERCA2a-expressing lentivirus improves myocardial function in doxorubicin-induced heart failure |
| Q73209566 | Lake Tahoe invitation meeting 2002 |
| Q40703867 | Left ventricular targeting of reporter gene expression in vivo by human BNP promoter in an adenoviral vector |
| Q40445304 | Lipidoid mRNA Nanoparticles for Myocardial Delivery in Rodents |
| Q46964433 | Mechanical and metabolic rescue in a type II diabetes model of cardiomyopathy by targeted gene transfer |
| Q34584027 | Mixed signals in heart failure: cancer rules |
| Q26823061 | Model-specific selection of molecular targets for heart failure gene therapy |
| Q45868301 | Modified mRNAs in the Cardiovascular System: A New Platform for Gene Therapy |
| Q45862464 | Molecular Cardiac Surgery with Recirculating Delivery (MCARD): Procedure and Vector Transfer |
| Q34658321 | Molecular and cellular mechanisms of myocardial remodeling |
| Q37099714 | Molecular basis of diastolic dysfunction. |
| Q34503413 | Myocardial gene therapy |
| Q35631316 | Myocardial regeneration: present and future trends. |
| Q34782396 | New molecular insights into heart failure and cardiomyopathy: potential strategies and therapies |
| Q34134407 | Positron emission tomography imaging of cardiac reporter gene expression in living rats |
| Q46921446 | Preservation of mechanical and energetic function after adenoviral gene transfer in normal rat hearts |
| Q36803909 | Radionuclide reporter gene imaging for cardiac gene therapy |
| Q34114279 | Recent developments in gene therapy for cardiac disease |
| Q40492563 | Receptor-interacting protein 140 overexpression impairs cardiac mitochondrial function and accelerates the transition to heart failure in chronically infarcted rats |
| Q37822275 | Refilling Intracellular Calcium Stores |
| Q35933316 | Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins |
| Q79105456 | Risk stratification and management of sudden cardiac death: a new paradigm |
| Q28291290 | S100A1 gene therapy for heart failure: A novel strategy on the verge of clinical trials |
| Q38129803 | Stem cell therapy for electrophysiological disorders. |
| Q36327036 | Stem cells as biological heart pacemakers |
| Q53580927 | Targeted gene transfer increases contractility and decreases oxygen cost of contractility in normal rat hearts. |
| Q28259868 | Targeting S100A1 in heart failure |
| Q35037546 | Targeting calcium cycling proteins in heart failure through gene transfer |
| Q35095401 | Targeting signaling pathways in heart failure by gene transfer |
| Q46285770 | The effects of intracellular Ca2+ on cardiac K+ channel expression and activity: novel insights from genetically altered mice |
| Q45883536 | Thoracoscopic monitoring for pericardial application of local drug or gene therapy |
| Q45858433 | Three catheter-based strategies for cardiac delivery of therapeutic gelatin microspheres |
| Q36126734 | Transcriptomic biomarkers for individual risk assessment in new-onset heart failure |
| Q33834104 | Transfer of the full-length dystrophin-coding sequence into muscle cells by a dual high-capacity hybrid viral vector with site-specific integration ability |
| Q74043498 | [New pharmacological agents in heart failure] |
| Q80106735 | [Rationale and clinical evidence for the effects of new pharmacological treatments for heart failure] |
Search more.